Casi Pharmaceuticals Inc (CASI)

$0.76 -0.01 (-1.08%)
Market Cap 9.41M
Revenue (ttm) 28.54M
Net Income (ttm) -39.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.56%
Debt to Equity Ratio -0.66
Volume 44,500
Avg Vol 35,762
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 7%
Beta 0.91
Analysts Sell
Price Target $4.00

Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 10 6508 6063
Address:
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China
JGroove
JGroove Feb. 23 at 4:30 PM
$CASI low float….monitoring for any trigger
0 · Reply
CapitalPinnacle
CapitalPinnacle Feb. 17 at 1:30 PM
$CASI China biotech; regulatory risks.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:44 AM
$CASI RSI: 37.74, MACD: -0.0403 Vol: 0.08, MA20: 0.94, MA50: 0.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_EmproX
_EmproX Feb. 16 at 10:19 PM
$FSLY $CNET $CASI $KSCP ++
0 · Reply
TinyTiger19
TinyTiger19 Feb. 15 at 8:41 PM
$CNET $CASI $KSCP $GREE 1:
0 · Reply
VelvetVestor
VelvetVestor Feb. 9 at 3:39 PM
$CASI Chinese American biotech; bridges two regulatory systems, adding complexity.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 4:07 PM
$CASI RSI: 69.72, MACD: 0.0091 Vol: 0.12, MA20: 0.88, MA50: 1.02 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Jan. 15 at 2:22 PM
$CASI 09:05 on Jan. 15 2026 CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:18 PM
$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:08 PM
$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas
0 · Reply
Latest News on CASI
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

Jan 15, 2026, 9:00 AM EST - 5 weeks ago

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

Dec 23, 2025, 4:05 PM EST - 2 months ago

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

Dec 11, 2025, 9:00 AM EST - 2 months ago

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 8, 2025, 9:00 AM EST - 2 months ago

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

CASI Pharmaceuticals Announces Changes in Board Governance

Nov 19, 2025, 9:00 AM EST - 3 months ago

CASI Pharmaceuticals Announces Changes in Board Governance

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

Nov 14, 2025, 4:05 PM EST - 3 months ago

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

Nov 10, 2025, 4:05 PM EST - 3 months ago

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Nov 4, 2025, 9:00 AM EST - 3 months ago

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:01 AM EST - 4 months ago

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

CASI Pharmaceuticals Appoints James Huang to Board of Directors

Sep 26, 2025, 9:45 AM EDT - 5 months ago

CASI Pharmaceuticals Appoints James Huang to Board of Directors

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Sep 8, 2025, 9:00 AM EDT - 6 months ago

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:00 AM EDT - 6 months ago

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

Sep 2, 2025, 9:00 AM EDT - 6 months ago

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

Aug 29, 2025, 4:05 PM EDT - 6 months ago

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Aug 28, 2025, 9:00 AM EDT - 6 months ago

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

Aug 4, 2025, 9:00 AM EDT - 7 months ago

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

Jul 21, 2025, 4:05 PM EDT - 7 months ago

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Provides Business and Clinical Update

May 19, 2025, 9:00 AM EDT - 10 months ago

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 16, 2025, 8:00 AM EDT - 10 months ago

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

May 12, 2025, 8:00 AM EDT - 10 months ago

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

May 7, 2025, 8:00 AM EDT - 10 months ago

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

Apr 3, 2025, 8:00 AM EDT - 11 months ago

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Mar 31, 2025, 8:15 AM EDT - 11 months ago

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Jan 6, 2025, 8:00 AM EST - 1 year ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Nov 15, 2024, 8:00 AM EST - 1 year ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Oct 24, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Sep 4, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Aug 16, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 19, 2024, 5:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jul 8, 2024, 7:30 AM EDT - 1 year ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:15 PM EDT - 1 year ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

Jun 26, 2024, 4:10 PM EDT - 1 year ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 15, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

May 14, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Mar 5, 2024, 7:00 AM EST - 2 years ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Feb 16, 2024, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 14, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Nov 8, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 11, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 2 years ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

May 17, 2023, 7:35 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 9:49 AM EDT - 3 years ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Apr 26, 2023, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Mar 21, 2023, 4:30 PM EDT - 3 years ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 8:42 AM EST - 3 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Jan 6, 2023, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

JGroove
JGroove Feb. 23 at 4:30 PM
$CASI low float….monitoring for any trigger
0 · Reply
CapitalPinnacle
CapitalPinnacle Feb. 17 at 1:30 PM
$CASI China biotech; regulatory risks.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:44 AM
$CASI RSI: 37.74, MACD: -0.0403 Vol: 0.08, MA20: 0.94, MA50: 0.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_EmproX
_EmproX Feb. 16 at 10:19 PM
$FSLY $CNET $CASI $KSCP ++
0 · Reply
TinyTiger19
TinyTiger19 Feb. 15 at 8:41 PM
$CNET $CASI $KSCP $GREE 1:
0 · Reply
VelvetVestor
VelvetVestor Feb. 9 at 3:39 PM
$CASI Chinese American biotech; bridges two regulatory systems, adding complexity.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 4:07 PM
$CASI RSI: 69.72, MACD: 0.0091 Vol: 0.12, MA20: 0.88, MA50: 1.02 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Jan. 15 at 2:22 PM
$CASI 09:05 on Jan. 15 2026 CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:18 PM
$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:08 PM
$CASI 09:02 on Jan. 12 2026 CASI Pharmaceuticals Presented Additional Data From Phase 1 Study Of CID-103 In Chronic Immune Thrombocytopenia On Dec. 7 #tradeideas
0 · Reply
MrDaily
MrDaily Jan. 10 at 1:59 PM
$CASI after the reverse split you’d have to be insane to take a 1.15/share to sell this
0 · Reply
agamemnus
agamemnus Jan. 9 at 5:02 PM
$CASI $1.15 acquisition proposal by biggest shareholder. https://archive.fast-edgar.com/20260109/AUB2K22C8222P2Z2222I2MZZ5H92R2X2N282/
0 · Reply
V9RDPUMA
V9RDPUMA Jan. 9 at 2:07 PM
$CASI Rare disease play
0 · Reply
ClassiTrader
ClassiTrader Jan. 9 at 12:11 AM
$CASI 💪
0 · Reply
JGroove
JGroove Jan. 5 at 5:03 PM
$CASI when does the appeal expire?
1 · Reply
MarketMomentumGuide
MarketMomentumGuide Dec. 27 at 8:21 AM
$CASI Positioning is increasingly shaped by how predictably management executes. Cash discipline will likely dictate investor patience. Any deterioration in traction could reset expectations abruptly. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 5:03 PM
$CASI Current Stock Price: $0.77 Contracts to trade: $2.5 CASI Jan 16 2026 Call Entry: $0.09 Exit: $0.17 ROI: 87% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DefendDomain
DefendDomain Dec. 26 at 5:59 AM
$CASI Market expectations are recalibrating toward measurable delivery and away from assumptions. Operational consistency must improve quarter by quarter. Capital misallocation remains the key downside risk. Ultimately, this is a case where delivery will decide trajectory.
0 · Reply
DARKP00L
DARKP00L Dec. 11 at 2:35 PM
$CASI 09:12 on Dec. 11 2025 CASI Pharmaceuticals Secures $20M Convertible Note Investment To Fund Phase 1 Renal Transplant Study In China #tradeideas
0 · Reply
MarketPlumber
MarketPlumber Dec. 9 at 6:39 AM
$CASI china scam
0 · Reply